Drug Profile
PB 201
Alternative Names: PB-201; PF-04937319; PF-4937319; WI-0800Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Pfizer
- Developer PegBio; Pfizer
- Class Amides; Antihyperglycaemics; Benzofurans; Pyrazines; Pyrimidines; Small molecules
- Mechanism of Action Glucokinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Type 2 diabetes mellitus
Most Recent Events
- 13 Apr 2022 PegBio plans a phase III trial for Type 2 diabetes mellitus (Adjunctive therapy) in China (PO), in May 2022 (NCT05326490)
- 01 Jan 2022 Phase-III clinical trials in Type 2 diabetes mellitus (Treatment-naive) in China (PO) (NCT05102149)
- 01 Nov 2021 PegBio plans a phase III trial for Type 2 diabetes mellitus (Treatment-naïve, In adults, In the elderly) in December 2021 (PO) (NCT05102149)